Opinion: China’s New Supply‑Chain Rules Could Disrupt Western Biopharma
A Stat News opinion piece cites a recent paper showing China’s rise to the world’s leading trial volume and warns that its newly tightened supply‑chain regulations may pose major logistical and regulatory challenges for Western pharmaceutical companies.